Third Age Health will acquire 75% of New Zealand asbestos specialist Consultex Group for $3.75 million, adding a new Testing, Inspection & Compliance vertical. The deal will be funded through existing cash and bank debt, with settlement expected by 30 November 2026.
- 75% Consultex stake agreed at a $3.75 million consideration
- Consultex reported approximately $1.13 million FY26 Adjusted EBITDA
- Acquisition funded through existing cash and bank debt
- Founder William Morris-Whyte retains 25% and remains managing director
- Settlement targeted for 30 November 2026, subject to customary conditions
Third Age Health Enters Asbestos Compliance
Third Age Health Services Limited (NZX:TAH) is moving beyond its healthcare base with an agreement to acquire 75% of Consultex Group, a New Zealand provider of asbestos surveying, assessment, testing, monitoring and advisory services. The consideration is $3.75 million for the stake, based on a $5.0 million valuation for the whole business, although the announcement does not specify the currency.
Consultex generated approximately $1.13 million of FY26 Adjusted EBITDA, according to unaudited special purpose financial statements. Those figures include adjustments for non-recurring and owner-related items, making the headline earnings measure useful for framing the transaction but not directly comparable with audited statutory profit. The purchase will draw on Third Age Health's existing cash and bank debt; the company has not disclosed the split or the financing terms.
Regulated Demand Creates the Investment Case
Consultex operates nationally with WorkSafe-licensed asbestos assessors and IANZ-accredited laboratory capability. WorkSafe estimates asbestos-related disease causes about 220 deaths a year in New Zealand and says buildings built or renovated before 2000 may contain asbestos, while regulations require identification and management of the material in specified circumstances.
That gives the acquisition a different industry profile from Third Age Health's ARC Medical Services business, but the company points to a similar operating model: specialist expertise, regulated customers, relatively modest capital requirements and the potential to generate free cash flow. The strategic logic is therefore not a healthcare adjacency so much as a bet on small, essential services that customers must address to meet health and safety obligations.
The deal arrives shortly after Third Age Health's FY26 acquisition strategy helped drive revenue and profit growth, according to its June result. Consultex will be run on a decentralised basis under its existing management, with founder William Morris-Whyte retaining a 25% interest and continuing as managing director. That structure leaves operational control with the team that built the business over the past six years, while giving Third Age Health majority ownership.
Funding and Completion Remain the Next Tests
Consultex is expected to become the first business in a new Testing, Inspection & Compliance vertical. Settlement is targeted for 30 November 2026, subject to customary conditions and completion adjustments. The immediate questions are how much debt the transaction adds, whether the Adjusted EBITDA converts into cash flow after acquisition, and how quickly the new vertical can become a meaningful contributor alongside the company's existing medical operations.
Bottom Line?
The acquisition broadens Third Age Health's earnings base, but its early value will depend on debt discipline and Consultex's ability to sustain cash generation under new ownership.
Questions in the middle?
- What proportion of the $3.75 million consideration will be funded with bank debt, and on what terms?
- How will Consultex's unaudited Adjusted EBITDA translate into audited earnings and free cash flow?
- Can the new Testing, Inspection & Compliance vertical support further acquisitions without diluting management focus?